View Item 

Show simple item record

Advanced Heart Failure: A Call to Action
dc.contributor.authorRussell, Stuart D.en_US
dc.contributor.authorMiller, Leslie W.en_US
dc.contributor.authorPagani, Francis D.en_US
dc.date.accessioned2010-06-01T20:03:21Z
dc.date.available2010-06-01T20:03:21Z
dc.date.issued2008-11en_US
dc.identifier.citationRussell, Stuart D.; Miller, Leslie W.; Pagani, Francis D. (2008). "Advanced Heart Failure: A Call to Action." Congestive Heart Failure 14(6): 316-321. <http://hdl.handle.net/2027.42/73182>en_US
dc.identifier.issn1527-5299en_US
dc.identifier.issn1751-7133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73182
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19076855&dopt=citationen_US
dc.format.extent179222 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2008 Le Jacqen_US
dc.titleAdvanced Heart Failure: A Call to Actionen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumthe Department of Cardiothoracic Surgery, University of Michigan Hospital, Ann Arbor, MIen_US
dc.contributor.affiliationotherFrom the Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD;en_US
dc.contributor.affiliationotherthe Division of Cardiology, Department of Medicine, Georgetown University Medical Center, Washington, DC;en_US
dc.identifier.pmid19076855en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73182/1/j.1751-7133.2008.00022.x.pdf
dc.identifier.doi10.1111/j.1751-7133.2008.00022.xen_US
dc.identifier.sourceCongestive Heart Failureen_US
dc.identifier.citedreferenceThom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113: e85 – e151.en_US
dc.identifier.citedreferenceNohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002; 287: 628 – 640.en_US
dc.identifier.citedreferenceJessup M, Brozena S. Heart failure. N Engl J Med. 2003; 348: 2007 – 2018.en_US
dc.identifier.citedreferenceHunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult – summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2005; 112: 1825 – 1852.en_US
dc.identifier.citedreferenceAdams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J. 1998; 135: S204 – S215.en_US
dc.identifier.citedreferenceHunt SA, Baker DW, Chin MH, et al. American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001; 38: 2101 – 2113.en_US
dc.identifier.citedreferenceTaylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third Official Adult Heart Transplantation Report – 2006. J Heart Lung Transplant. 2006; 25: 869 – 879.en_US
dc.identifier.citedreferenceCuffe MS, Califf RM, Adams KF Jr, et al; for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287: 1541 – 1547.en_US
dc.identifier.citedreferenceHershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory advanced stage heart failure. J Card Fail. 2003; 9: 180 – 187.en_US
dc.identifier.citedreferenceStevenson LW, Miller LW, Desvigne-Nickens P, et al; for the REMATCH Investigators. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation. 2004; 110: 975 – 981.en_US
dc.identifier.citedreferenceAaronson KD, Eppinger MJ, Dyke DB, et al. Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol. 2002; 39 ( 8 ): 1247 – 1254.en_US
dc.identifier.citedreferenceBhat G. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy. ASAIO J. 2006; 52: 677 – 681.en_US
dc.identifier.citedreferenceRose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001; 345: 1435 – 1443.en_US
dc.identifier.citedreferenceLong JW, Kfoury AG, Slaughter MS, et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail. 2005; 11: 133 – 138.en_US
dc.identifier.citedreferenceLietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007; 116: 497 – 505.en_US
dc.identifier.citedreference16 Effect of enalapril on mortality and the development of heart failure I asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992; 327: 685 – 691.en_US
dc.identifier.citedreferenceBenedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD investigators. Circulation. 1996; 94: 690 – 697.en_US
dc.identifier.citedreferenceDries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol. 1998; 32: 695 – 703.en_US
dc.identifier.citedreferenceDries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35: 681 – 689.en_US
dc.identifier.citedreferenceQuinones MA, Greenberg BH, Kopelen HA, et al.; for the SOLVD Investigators. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD Registry and Trials: significance of left ventricular hypertrophy. J Am Coll Cardiol. 2000; 35: 1237 – 1244.en_US
dc.identifier.citedreferenceDomanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003; 42: 705 – 708.en_US
dc.identifier.citedreferenceMancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991; 83: 778 – 786.en_US
dc.identifier.citedreferenceAaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997; 95: 2660 – 2667.en_US
dc.identifier.citedreferenceChin MH, Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol. 1997; 79: 1640 – 1644.en_US
dc.identifier.citedreferenceAlla F, Briancon S, Juilliere Y, et al; for the EPICAL Investigators. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. Am Heart J. 2000; 139: 895 – 904.en_US
dc.identifier.citedreferenceCowie MR, Wood DA, Coats AJS, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000; 83: 505 – 510.en_US
dc.identifier.citedreferenceJong P, Vowinchel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure. Arch Intern Med. 2002; 162: 1689 – 1694.en_US
dc.identifier.citedreferenceBouvy ML, Heerdink ER, Leufkens HGM, et al. Predicting mortality in patients with heart failure: a pragmatic approach. Heart. 2003; 89: 605 – 609.en_US
dc.identifier.citedreferenceLee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure. Derivation and validation of a clinical model. JAMA. 2003; 290: 2581 – 2587.en_US
dc.identifier.citedreferenceKittleson M, Hurwitz S, Shah MR, et al. Development of circulatory–renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol. 2003; 41: 2029 – 2035.en_US
dc.identifier.citedreferenceFelker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004; 10: 4604 – 4666.en_US
dc.identifier.citedreferenceFonarow GC, Adams KF, Abraham WT, et al; for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293: 572 – 580.en_US
dc.identifier.citedreferenceRector TS, Ringwala SN, Ringwala SN, et al. Validation of a risk score for dying within 1 year of an admission for heart failure. J Card Fail. 2006; 12: 276 – 280.en_US
dc.identifier.citedreferenceRohde LE, Goldraich L, Polanczyk CA, et al. A simple clinically based predictive rule for heart failure in-hospital mortality. J Card Fail. 2006; 12: 587 – 593.en_US
dc.identifier.citedreferenceMahon NG, Blackstone EH, Francis GS, et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 2002; 40: 1106 – 1113.en_US
dc.identifier.citedreferenceEshagian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97: 1759 – 1764.en_US
dc.identifier.citedreferenceGreenberg B, Lottes SR, Nelson JJ, et al. Predictors of clinical outcomes in patients given carvedilol for heart failure. Am J Cardiol. 2006; 98: 1480 – 1484.en_US
dc.identifier.citedreferenceLevy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model. Prediction of survival in heart failure. Circulation. 2006; 113: 1424 – 1433.en_US
dc.identifier.citedreferenceTeuteberg JJ, Lewis EF, Nohria A, et al. Characteristics of patients who die with heart failure and a low ejection fraction in the new millennium. J Cardiac Fail. 2006; 12: 47 – 53.en_US
dc.identifier.citedreferenceStewart GC, Brooks K, Tsang SW, et al. Heart failure patients define threshold for left ventricular assist devices. Circulation. 2006; 114 ( suppl II ): II – 484.en_US
dc.identifier.citedreferenceSaxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) trial. Circulation. 2006; 114: 2766 – 2772.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1751-7133.2008.00022.x.pdf
Size:
175.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.